Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Inclusion Criteria: * CML Ph+ (assessed by cytogenetic or FISH) * Age ≥ 18 year at inclusion * PS grade 0 to 2 (ECOG) * previous allogeneic stem cell transplantation * molecular, cytogenetic or haematological relapse in chronic phase after transplantation * Immune therapy for graft versus host disease stopped within 2 months from inclusion * Adequate and organ function, defined as the following: total bilirubin \<3x uln, sgpt \<3x uln, creatinine \<2x uln. * informed consent sign up Exclusion Criteria: * Age less than 18 y * accelerated or blastic phase * previous therapy with imatinib * active malignancy other than CML or non-melanoma cancer of the skin * current treatment with another investigational agent